Business
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with
About this update from Pepgen Inc.
[{"type":"text","content":" BOSTON--(BUSINESS WIRE)--\nPepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting a short oral presentation as well as five posters at the 29th Annual Congress of the World Muscle Society (WMS), being held October 8-12, 2024 in Prague, Czech Republic.\n\n“We are pleased to be presenting preclinical and clinical data on our Duchenne muscular dystrophy and myotonic dystrophy type 1 programs at this premier global muscle meeting,” said James McArthur, PhD, President and CEO of PepGen. “Based on the totality of data in both our 5 mg/kg cohort and the ongoing 10 mg/kg cohort in the CONNECT1-EDO51 trial as of October 3, we believe PGN-EDO51 has a favorable emerging safety profile. There have been no serious adverse events, and all treatment-related adverse events have been mild and have resolved. Hypomagnesemia was observed in one patient and resolved with oral supplementation. All participants continue in the study as planned, with no discontinuations, dose interruptions or reductions.”\n\nPGN-EDO51: Duchenne Muscular Dystrophy (DMD)\nShort Oral Title: CONNECT1-EDO51: A 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping\nPresentation Number: #403P\nSession: Short Oral Presentations 6 - Terrace 2B\nDate & Time: October 9th at 6:15-6:45pm CEST\nPresenter: Michelle Mellion, MD, Chief Medical Officer\n\nPoster Title: CONNECT1-EDO51: A 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping\nPoster Number: #403P\nSession: Poster Session 2 - Forum Hall\nDate & Time: October 9th at 5:15-6:15pm CEST\nPresenter: Michelle Mellion, MD, Chief Medical Officer\n\nPoster Title: CONNECT2-EDO51: A Phase 2 placebo-controlled study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping\nPoster Number: #404P\nSession: Poster Session 2 - Forum Hall\nDate & Time: October 9th at 5:15-6:15pm CEST\nPresenter: Michelle Mellion, MD, Chief Medical Officer\n\nPoster Title: Single- and repeat-dose nonclinical data for PGN-EDO51 demonstrated favorable pharmacology...